All Oncology News

The FDA granted priority review to the NDA seeking the approval of revumenib for the treatment of relapsed/refractory, KMT2A-rearranged acute leukemia.

Pierre Gholam, MD, discusses primary considerations for the first-line treatment of patients with advanced, unresectable HCC.

Neeraj Agarwal, MD, FASCO, discusses unmet needs across the prostate cancer spectrum and ongoing trials investigating agents in earlier settings.

Osimertinib plus chemotherapy confers superior post-progression survival outcomes vs osimertinib alone in patients with EGFR-mutated NSCLC.

Rutgers Cancer Institute of New Jersey along with RWJBarnabas Health was redesignated by the National Cancer Institute.

The Japanese Ministry of Health, Labour and Welfare has approved zolbetuximab for CLDN18.2-positive, unresectable, advanced or recurrent gastric cancer.

Positive phase 2a topline findings have been announced with SLS009 plus azacitidine and venetoclax in relapsed/refractory acute myeloid leukemia.

Sunil Iyer, MD, expands on the impact of the FDA’s approval of luspatercept on the management of lower-risk myelodysplastic syndrome.

Recent report details the issues early-career oncologists experience regarding parental leave.

Saad J. Kenderian, MB, CHB, expands on the significance of liso-cel’s approval in chronic lymphocytic leukemia or small lymphocytic lymphoma.

Anlotinib plus etoposide, carboplatin, and placebo improved PFS vs etoposide plus carboplatin and 2 placebos in first-line ES-SCLC.

Durvalumab/chemoradiation did not significantly improve survival vs chemoradiation alone in patients with unresectable non–small cell lung cancer.

Robert Dreicer, MD, discusses the complex landscape of prostate cancer treatment, highlighting key points from his presentation at the 2024 NY GU.

Liposomal annamycin plus cytarabine elicited responses in patients with acute myeloid leukemia, according to interim data from the phase 1b/2 MB-106 trial.

Joseph G. Jurcic, MD, highlights findings from the phase 3 SIMPLIFY-1, SIMPLIFY-2, and MOMENTUM trials in myelofibrosis.

The FDA issued complete response letters to the BLA for odronextamab in relapsed/refractory follicular lymphoma and diffuse large B-cell lymphoma.

Amer Zeidan, MBBS, MHS, has been appointed inaugural chief of the Division of Hematologic Malignancies at Yale Cancer Center.

Two items in the medical world should send chills down the spines of those considering the possible financial future of oncology care in the United States.

Mary-Ellen Taplin, MD, discusses ways to mitigate health care disparities in the treatment of patients with prostate cancer.

Adjuvant atezolizumab did not provide a clinical benefit when added to chemotherapy in patients with triple-negative breast cancer.

Patients with non–small cell lung cancer treated on the IMscin002 trial preferred subcutaneous atezolizumab vs the intravenous formulation.

A matching-adjusted indirect comparison shows that brexu-cel is superior to pirtobrutinib regarding response and survival in relapsed/refractory MCL.

The FDA has granted regular approval to mirvetuximab soravtansine-gynx for select patients with pretreated FRα-positive, platinum-resistant ovarian cancer.

Joseph G. Jurcic, MD, discusses the benefits and limitations of several JAK inhibitors for patients with myelofibrosis.

Damian Green, MD, will join Sylvester Comprehensive Cancer Center this spring to lead its transplantation and cellular therapy services.

The EMA’s CHMP has recommended the approval of enzalutamide with or without androgen deprivation therapy in biochemically recurrent nmHSPC.

PT886 has been granted fast track designation for use as a potential therapeutic option in patients with metastatic claudin 18.2–positive pancreatic adenocarcinoma.

Shanta Dhar, PhD, FRSC, discusses the significance of being named a fellow of the National Academy of Inventors for her research in prostate cancer.

Ribociclib plus a nonsteroidal aromatase inhibitor bested nonsteroidal aromatase inhibitor therapy alone in terms of iDFS in early-stage breast cancer.

Avutometinib plus defactinib led to tumor regression in most heavily pretreated patients with recurrent low-grade serous ovarian cancer.